Dr. Richard Brown -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Richard Brown, a Internal Medicine physician based in Jersey City, NJ. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Richard Brown has received $74,926.39 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Richard Brown
- Medical Specialty: Internal Medicine
- Practice Location: Jersey City, NJ, New Jersey
- NPI Number: 1655472649
- Transparency Score: 50/100
- Payment Records Span: 2025-07-26 to 2025-07-26
Payment Summary
Dr. Richard Brown has received a total of $74,926.39 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $74,926.39 per transaction.
- Total Payments Received: $74,926.39
- Number of Transactions: 1
- Average Payment: $74,926.39
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Internal Medicine. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Richard Brown's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Ownership Interest | $74,926.39 | Ownership stakes, dividends, and investment returns |
The largest payment category for Dr. Richard Brown is Ownership Interest, accounting for 100% ($74,926.39) of total pharmaceutical payments received. This indicates a financial ownership interest in a pharmaceutical or medical device company.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Richard Brown. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Pfizer Inc | $74,926.39 | 1 |
Dr. Richard Brown has a financial relationship with Pfizer Inc, receiving $74,926.39 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Richard Brown. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Imbruvica -- Referenced in payment records from pharmaceutical companies to Dr. Richard Brown
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Richard Brown's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Richard Brown, an Internal Medicine specialist in Jersey City, NJ, has a pharmaceutical payment profile marked by a single, substantial transaction. With a total of $74,926.39 from pharmaceutical companies, this amount is significantly higher than the typical payment volume for physicians in Internal Medicine. While the average Internal Medicine physician may receive payments in the low thousands annually, Dr. Brown's single payment represents a considerable outlier. The entirety of this payment originates from Pfizer Inc., indicating a concentrated relationship with this specific pharmaceutical giant. This singular, large payment, designated as 'ownership' and dated July 26, 2025, suggests a potential financial stake in the company or its products, rather than routine payments for consulting, speaking, or meals. Such a concentrated and substantial payment, particularly one related to ownership, warrants careful consideration. While pharmaceutical companies do engage physicians for legitimate reasons such as research, advisory roles, and educational activities, a large payment tied to ownership can raise questions about potential conflicts of interest. It is crucial to understand that 'ownership' payments can encompass various scenarios, from holding stock to more direct financial interests. The pattern here, with one large payment rather than numerous smaller ones, does not suggest routine professional engagement but rather a significant, singular financial tie. For patients, understanding these financial relationships is key to informed healthcare decisions. While not all pharmaceutical payments indicate bias, they do highlight potential influences that could shape a physician's treatment recommendations or prescribing habits. Patients should be aware that even indirect financial ties can create perceptions of bias, and transparency is vital for maintaining trust in the doctor-patient relationship. This profile suggests that Dr. Brown has a significant financial relationship with Pfizer, which patients should consider when discussing treatment options, especially those involving Pfizer products.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Richard Brown is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's financial relationships with pharmaceutical companies, it's important to maintain a balanced perspective. Many physicians engage with drug manufacturers for legitimate reasons, such as participating in clinical trials, providing expert advice on drug development, or educating other healthcare professionals. These activities can contribute to medical advancements and improved patient care. However, it's also true that financial ties can create potential conflicts of interest. At your next appointment, consider asking your doctor about their relationships with pharmaceutical companies, especially if they are prescribing a new medication or recommending a treatment that is particularly expensive. You might ask, 'Do you have any financial relationships with the companies whose medications you prescribe?' or 'Are there alternative treatments available that might be more cost-effective?' Red flags to watch for include a doctor who seems overly insistent on a particular brand-name drug without a clear clinical justification, or who consistently prescribes the most expensive options when equally effective, less costly alternatives exist. It's normal for doctors to receive occasional payments for legitimate professional activities. However, a pattern of large, frequent payments, especially for speaking or consulting, or a significant financial stake (like ownership) in a company whose products they prescribe, might warrant closer attention. Remember, transparency is key. You have the right to understand potential influences on your care. Evaluating your doctor's prescribing patterns involves looking at whether they consider a range of treatment options, discuss costs, and prioritize your individual health needs above all else.
Peer Comparison: How Dr. Richard Brown Compares to Other Internal Medicine Physicians
Dr. Brown's total pharmaceutical payment of $74,926.39 from a single transaction is substantially higher than the average for Internal Medicine physicians. While many Internal Medicine doctors receive payments totaling a few thousand dollars annually across various categories, Dr. Brown's profile is dominated by one large 'ownership' payment. This places him significantly above the typical payment volume and suggests a different nature of financial engagement compared to his peers.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Richard Brown in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Pfizer Inc | $74,926.39 | ownership | Imbruvica | 2025-07-26 | Not Assessed |
Frequently Asked Questions About Dr. Richard Brown's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Richard Brown taking too much pharma money?
Dr. Brown's total pharmaceutical payment of $74,926.39 is from a single 'ownership' transaction with Pfizer Inc. While this amount is substantial and significantly higher than the average for Internal Medicine physicians, it's crucial to understand the nature of 'ownership' payments. If this represents a genuine financial investment or stake, it differs from routine payments for consulting or speaking. Without more context on the 'ownership' arrangement, it's difficult to definitively label it 'too much,' but the concentration and size of this single payment warrant patient awareness.
What pharma companies pay Dr. Richard Brown?
Dr. Richard Brown receives payments exclusively from Pfizer Inc. The total amount from this company is $74,926.39, representing his entire reported pharmaceutical payment volume.
Should I switch doctors because of pharma payments?
Switching doctors solely based on pharmaceutical payments is a significant decision. Consider the nature and volume of payments. A single, large 'ownership' payment, like Dr. Brown's, is different from numerous smaller payments for consulting or speaking. If your doctor consistently prescribes expensive medications without clear justification, seems unduly influenced by drug reps, or doesn't discuss alternatives, these might be bigger concerns than the payments themselves. Transparency is important; discuss any concerns with your doctor first.
What kinds of payments does this doctor receive?
Dr. Brown's reported payments consist solely of 'ownership' totaling $74,926.39. This indicates a financial stake or investment, rather than payments for services like consulting, speaking, research, or meals, which are not reported for him.
How do these payments compare to other Internal Medicine?
Dr. Brown's total payment of $74,926.39 is considerably higher than the average for Internal Medicine physicians, who typically receive payments in the low thousands annually. His profile is dominated by a single large 'ownership' payment, making his financial relationship with pharmaceutical companies distinct from the more common, smaller, and varied payments received by his peers.
Do pharma payments affect prescribing quality?
Research suggests that even small financial incentives from pharmaceutical companies can influence physician prescribing habits, often leading to increased prescribing of the associated drug. While not all payments indicate bias, and many are for legitimate professional activities, studies indicate a correlation between receiving payments and prescribing patterns. Patients should be aware of this potential influence and discuss treatment options openly with their doctors.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website, search for 'Richard Brown' and input his National Provider Identifier (NPI) number, 1655472649. This will allow you to view the detailed records of payments made to him by pharmaceutical and medical device companies.
Understanding This Doctor Payment Report
This transparency report for Dr. Richard Brown is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Internal Medicine physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Richard Brown's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Richard Brown and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Internal Medicine Specialty Payment Data -- See payment patterns for all internal medicine physicians
- New Jersey Physician Payments -- Browse pharmaceutical payments to physicians in New Jersey
- Internal Medicine Physicians in New Jersey -- Compare Dr. Richard Brown to peers in the same state and specialty
- Pfizer Inc Payment Profile -- View all payments made by Dr. Richard Brown's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Richard Brown's NPI (1655472649) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.